Treatment of Lupus Tumidus in the Absence of Severe or Disseminated Cutaneous Lupus Erythematosus Lesions

This first-line protocol addresses lupus tumidus in patients who do not have severe or disseminated cutaneous lupus erythematosus (CLE) skin lesions. Even without widespread disease, a structured systemic approach is indicated to achieve meaningful skin improvement.

Clinical Scenario

The patient presents with lupus tumidus in the absence of severe or disseminated cutaneous lupus erythematosus skin lesions. This subset requires its own treatment strategy, distinct from protocols reserved for more extensive or scarring CLE presentations.

Treatment Approach (Partial Overview)

Management in this setting centers on oral antimalarial drug therapy as the first-line systemic intervention, recommended also for long-term use. Specific agent selection, weight-based dosing, maximum dose thresholds, and the full structured regimen are available in the complete protocol →

Treatment goal: Improvement of cutaneous lupus erythematosus skin lesions after 16 weeks of treatment.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/ddg.14491

Topical glucocorticoids are recommended for treating circumscribed CLE lesions.

For extensive lesions, an inclination to scarring, or insufficient response, combination with a systemic treatment (antimalarial drug) is recommended.

Antimalarial drugs are recommended as first-line treatments, also for long-term therapy, in all CLE patients with severe and disseminated skin lesions; in particular for patients with a risk of scarring.

In CLE patients, for example, skin was ‘improved/remarkably improved’ more frequently with HCQ than with placebo after 16 weeks of treatment (51 % versus 9 %).

View source ↗